Accelerate Diagnostics Inc., alongside its US subsidiary, has filed for Chapter 11 bankruptcy as part of a restructuring effort. On May 30, 2025, the company entered into a "stalking horse" asset purchase agreement with an affiliate of Indaba Capital Management, L.P., its current secured noteholder. This agreement aims to sell substantially all of the company's assets. The transaction will be conducted under Section 363 of the Bankruptcy Code, requiring court approval and a bidding process to solicit potentially higher offers. The proceedings are accessible online through the company's claims agent, Stretto, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.